BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 19038308)

  • 21. Reductive 17beta-hydroxysteroid dehydrogenases which synthesize estradiol and inactivate dihydrotestosterone constitute major and concerted players in ER+ breast cancer cells.
    Zhang CY; Wang WQ; Chen J; Lin SX
    J Steroid Biochem Mol Biol; 2015 Jun; 150():24-34. PubMed ID: 25257817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause.
    Liu ZJ; Lee WJ; Zhu BT
    Cancer Res; 2005 Jul; 65(13):5802-11. PubMed ID: 15994956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.
    Blouin K; Richard C; Brochu G; Hould FS; Lebel S; Marceau S; Biron S; Luu-The V; Tchernof A
    J Endocrinol; 2006 Dec; 191(3):637-49. PubMed ID: 17170221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Allan GM; Lawrence HR; Cornet J; Bubert C; Fischer DS; Vicker N; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 2006 Feb; 49(4):1325-45. PubMed ID: 16480268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cloning and characterization of human form 2 type 7 17beta-hydroxysteroid dehydrogenase, a primarily 3beta-keto reductase and estrogen activating and androgen inactivating enzyme.
    Liu H; Robert A; Luu-The V
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):173-9. PubMed ID: 15862963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The selective estrogen enzyme modulators in breast cancer: a review.
    Pasqualini JR
    Biochim Biophys Acta; 2004 Jun; 1654(2):123-43. PubMed ID: 15172700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudo-symmetry of C19 steroids, alternative binding orientations, and multispecificity in human estrogenic 17beta-hydroxysteroid dehydrogenase.
    Gangloff A; Shi R; Nahoum V; Lin SX
    FASEB J; 2003 Feb; 17(2):274-6. PubMed ID: 12490543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New development in intracrinology of breast carcinoma.
    Sasano H; Suzuki T; Nakata T; Moriya T
    Breast Cancer; 2006; 13(2):129-36. PubMed ID: 16755106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
    Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
    J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study.
    Song D; Liu G; Luu-The V; Zhao D; Wang L; Zhang H; Xueling G; Li S; Désy L; Labrie F; Pelletier G
    J Steroid Biochem Mol Biol; 2006 Oct; 101(2-3):136-44. PubMed ID: 16930994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
    Shibuya R; Suzuki T; Miki Y; Yoshida K; Moriya T; Ono K; Akahira J; Ishida T; Hirakawa H; Evans DB; Sasano H
    Endocr Relat Cancer; 2008 Mar; 15(1):113-24. PubMed ID: 18310280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
    Irahara N; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S
    Cancer Lett; 2006 Nov; 243(1):23-31. PubMed ID: 16556483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer.
    Smuc T; Rizner TL
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):74-82. PubMed ID: 18930784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
    Day JM; Tutill HJ; Purohit A; Reed MJ
    Endocr Relat Cancer; 2008 Sep; 15(3):665-92. PubMed ID: 18541621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells.
    Newman SP; Ireson CR; Tutill HJ; Day JM; Parsons MF; Leese MP; Potter BV; Reed MJ; Purohit A
    Cancer Res; 2006 Jan; 66(1):324-30. PubMed ID: 16397246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen inhibits cell proliferation through in situ production in human thymoma.
    Ishibashi H; Suzuki T; Suzuki S; Moriya T; Kaneko C; Nakata T; Sunamori M; Handa M; Kondo T; Sasano H
    Clin Cancer Res; 2005 Sep; 11(18):6495-504. PubMed ID: 16166425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New developments in intracrinology of human breast cancer: estrogen sulfatase and sulfotransferase.
    Sasano H; Nagasaki S; Miki Y; Suzuki T
    Ann N Y Acad Sci; 2009 Feb; 1155():76-9. PubMed ID: 19250194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development.
    Marchais-Oberwinkler S; Henn C; Möller G; Klein T; Negri M; Oster A; Spadaro A; Werth R; Wetzel M; Xu K; Frotscher M; Hartmann RW; Adamski J
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):66-82. PubMed ID: 21193039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
    Purohit A; Tutill HJ; Day JM; Chander SK; Lawrence HR; Allan GM; Fischer DS; Vicker N; Newman SP; Potter BV; Reed MJ
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):199-203. PubMed ID: 16414180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
    Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.